Twist Bioscience Corporation (NASDAQ: TWST) launched its Complex Genes service, expanding its DNA synthesis capabilities to include structurally complex and highly-engineered protein sequences up to 7,000 base pairs in length.

The company stated it expects to accept approximately 99.5% of clonal gene orders and 99.9% of all DNA products with the new offering. The service targets researchers working on nucleic acid therapeutics and AI-enabled drug discovery who require complex sequence elements that have historically been difficult to produce at commercial scale.

The Complex Genes service can synthesize sequences containing short tandem repeats, inverted repeats, long repeats, homopolymers up to 30 base pairs, and localized regions of high or low GC content. These features are commonly found in advanced promoters, UTRs, ITRs, secondary structures and GS linkers.

Twist utilizes its silicon-based DNA synthesis platform along with improved downstream processes in manufacturing, automation, and sequencing to produce these complex sequences. The company provides customers with complexity and manufacturability scores during the ordering process and delivers constructs ranging from 300 to 7,000 base pairs within 15 business days.

"As research in nucleic acid therapeutics and AI-guided protein design and therapeutics discovery accelerate, scientists need a reliable partner to consistently deliver genes rapidly at scale and with more complex sequences," said Emily M. Leproust, CEO and co-founder of Twist Bioscience.

The service supports AI-enabled drug discovery by allowing researchers to manufacture AI-generated sequences without altering them for manufacturability purposes. All Twist Clonal Genes can be cloned into catalog vectors or customer-selected vectors.

Information in this article is based on a company press release.